The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
CPX-351 granted approval in the EU for the treatment of therapy-related acute myeloid leukemia or AML-MRC
On 27th August 2018, the European Commission (EC) granted approval to CPX-351, 44 mg/100 mg powder for concentrate for solution for infusion for the treatment for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). This comes after the positive opinion recommending a marketing authorization for CPX-351 was given by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).1
The EC approval for CPX-351, a liposomal formulation of daunorubicin plus cytarabine co-encapsulated at a molar ratio of 1:5, was based on clinical data from five studies including the pivotal phase III study (NCT01696084), which evaluated the safety and efficacy of Vyxeos® compared to cytarabine and daunorubicin (7+3) in patients with newly diagnosed t-AML and AML-MRC. The results of this pivotal study were recently published by Jeffery Lancet et al. in the Journal of Clinical Oncology.2
Three-hundred and nine patients with newly diagnosed sAML were randomly assigned 1:1 to receive Vyxeos® (n = 153, mean age = 67.8 years) or 7+3 (n = 156, mean age = 67.7) as induction and consolidation chemotherapy. The primary endpoint of the study, overall survival (OS), was met with patients in the CPX-351 arm significantly had a longer OS compared to patients in the 7+3 arm (Median OS in the CPX-351 and 7+3 arms: 9.56 vs 5.95 months respectively, HR = 0.69 [95% CI, 0.52–0.90], P = 0.003).2
According to the drug manufacturer’s, Jazz Pharmaceuticals, “CPX-351is the first chemotherapy to demonstrate an OS advantage versus the standard of care in a phase III study of older adult patients with newly diagnosed t-AML or AML-MRC”.1
References